In a Phase 3 study, SB8 demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR) to reference bevacizumab AVASTIN® i in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
Safety, pharmacokinetics, and immunogenicity were also comparable
Marketing authorization application for SB8 accepted for review by the European Medicines Agency (EMA)
INCHEON, Korea -- (BUSINESS WIRE) --
Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference bevacizumab in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).ii The study results will be presented for the first time today at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
“Data from this study showed that there were no clinically meaningful differences between SB8 and reference bevacizumab in terms of efficacy, safety, pharmacokinetics and immunogenicity,” said Chul Kim, Senior Vice President and Head of Clinical Sciences Division, Samsung Bioepis. “We are committed to increasing access to high-quality, life-changing oncology medicines through the development of biosimilars to address some of oncology’s most pressing challenges.”
The primary endpoint of the study was the overall response rate (ORR) by 24 weeks; risk ratio was analyzed in the full analysis set (FAS) with pre-defined equivalence margin of 0.737 to 1.357 and the risk difference was analyzed in the per-protocol set (PPS) with pre-defined equivalence margin of ±12.5%. The ORR in FAS was 47.6% for SB8 and 42.8% for reference bevacizumab; the risk ratio was 1.11 (90% CI: 0.975, 1.269). The ORR in PPS was 50.1% for SB8 and 44.8% for reference bevacizumab; the risk difference was 5.3% (95% CI: −2.2%, 12.9%). The median progression-free survival (8.5 months vs 7.9 months) and overall survival (14.9 months vs. 15.8 months) were comparable between SB8 and reference bevacizumab. The overall incidence of treatment-emergent adverse events (92.1% vs 91.1%) and the incidence of overall anti-drug antibodies (16.1% vs 11.0%) were also comparable between SB8 and reference bevacizumab.
Marketing Authorization Application (MAA) for SB8 was accepted for review by the European Medicines Agency (EMA) in July 2019.
The results of the SB8 Phase 3 study will be presented as a poster during ESMO as follows: [1565P] 12:00-13:00, September 28, Hall 4. Samsung Bioepis will also host a satellite symposium, titled ‘Quality Assurance to Optimize HER2+ Breast Cancer Treatment’, which will discuss the importance of quality maintenance in oncology biologics. The symposium will take place between 13:00-14:30 on September 30, 2019 in Toledo Auditorium, Hall 5, Fira Gran Via, Barcelona. Topics include:
Building confidence in biosimilars
Acknowledging importance of biologics quality in clinical practice
Reassuring biosimilarity based on clinical evidence
Interactive discussion: perspective on biosimilars in oncology
SB8 Phase 3 Study
The SB8 Phase 3 study is a randomized, double-blind, multicenter study evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity of SB8 compared to reference bevacizumab in combination with paclitaxel and carboplatin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC). 763 patients were randomized (1:1) to receive SB8 or reference bevacizumab with paclitaxel and carboplatin Q3W followed by SB8 or reference bevacizumab maintenance therapy until disease progression, unacceptable toxicity, death, or 1 year from the randomization of the last patient. The primary endpoint is the overall response rate (ORR) which is defined as the proportion of patients whose best overall response by 24 weeks is either complete response or partial response. Secondary endpoints were progression free survival (PFS), overall survival (OS), duration of response (DOR), safety, PK, and immunogenicity.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen.
杨开刚:天生的画家,未来之巨匠
CES 2020圆满落幕:人工智能和5G定义创新的未来
NTT实现世界超快速石墨烯光电探测器零偏压运行
顶尖律所ROSEN鼓励Ocugen
Eaton InfiniTrac Electronic
2022年新冠疫情期间出台的灵活法律法规使跨国
绘锦绣画卷 ——庆祝中国共产党成立100周年杭
神策数据荣获北京市广播电视局优秀推荐项目
阳信二中参加中美中小学校长交流暨合作洽谈会
平度市人民法院:电视台对“无讼村庄(社区)
DOCOMO将携手海外合作伙伴进一步扩大5G试验
FarEye研究称糟糕的配送体验可能会让零售商失去
《六尺巷》音乐故事将于11月4日晚19点02分首登
香港桂冠论坛:召集天文学等领域的杰出青年科
焕多多——企业库存压力大,利用“易货”消库
投资者须知:顶级律师事务所ROSEN鼓励投资Fra
Novasec将为西班牙最大的陆上风电场筹资8,000万欧
One IBC基于高水平的客户满意度打造信任
Conviva的新数据揭示成功驾驭TikTok算法
“金沙用心”时刻守护您的旅行安全
武田以高达2.78亿美元的价格向Celltrion剥离亚
Xsolla创始人Shurick Agapitov
湖南省芷江检察院第一党支部开展12月份党日活
Market Access Transforma